ResMed
Stock Forecast, Prediction & Price Target
ResMed (RMD) stock Price Target by analysts
$237
Potential downside: -16.46%
ResMed price prediction
What is ResMed stock analysts` prediction?
ResMed stock forecast: Based on 2 Wall Street analysts` predicted price targets for ResMed in the last 3 months, the avarage price target is $237, with a high forecast of $NaN. The average price target represents a -16.46% change from the last price of $283.7.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
ResMed stock Price Target by analysts
Full breakdown of analysts given ResMed price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jonathan Block Stifel Nicolaus | 0% 0/1 | 10 months ago | $250 -11.87% downside | $242.51 | TheFly | Previous targets (0) |
Craig Wong-Pan RBC Capital | 33.33% 1/3 | 12 months ago | $224 -21.04% downside | $238.95 | StreetInsider | Previous targets (2) |
Joe Vruwink Robert W. Baird | 0% 0/1 | about 1 year ago | $280 -1.30% downside | $246.18 | StreetInsider | Previous targets (0) |
Mike Polark Wolfe Research | 0% 0/1 | about 1 year ago | $180 -36.55% downside | $250.88 | StreetInsider | Previous targets (0) |
Craig Wong-Pan RBC Capital | 33.33% 1/3 | over 1 year ago | $187 -34.08% downside | $194.27 | StreetInsider | Previous targets (2) |
Mike Matson Stifel Nicolaus | 0% 0/1 | over 1 year ago | $224 -21.04% downside | $198.03 | StreetInsider | Previous targets (0) |
Suraj Kalia Oppenheimer | 50% 1/2 | almost 2 years ago | $175 -38.31% downside | $134.65 | Benzinga | Previous targets (1) |
Mike Matson Needham | 100% 1/1 | about 2 years ago | $180 -36.55% downside | $153.89 | StreetInsider | Previous targets (0) |
Craig Wong-Pan RBC Capital | 33.33% 1/3 | over 3 years ago | $244 -13.99% downside | $197.57 | Pulse 2.0 | Previous targets (2) |
Suraj Kalia Oppenheimer | 50% 1/2 | almost 4 years ago | $312 9.97% upside | $253.77 | StreetInsider | Previous targets (1) |
Sean Laaman Morgan Stanley | 100% 1/1 | about 4 years ago | $250 -11.87% downside | $271.87 | StreetInsider | Previous targets (0) |
Anthony Petrone Jefferies | 100% 1/1 | about 4 years ago | $240 -15.40% downside | $264.75 | TheFly | Previous targets (0) |
ResMed Financial Estimates
ResMed Revenue Estimates
ResMed EBITDA Estimates
ResMed Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 6/30/2022 | 6/30/2023 | 6/30/2024 | 6/30/2026 | 6/30/2027 | 6/30/2028 | |
Revenue
% change YoY
| $3.57B N/A | $4.22B 18.02% | $4.68B 10.94% | Avg: $5.35B Low: $5.23B High: $5.46B avg. 14.24% | Avg: $5.69B Low: $5.57B High: $5.82B avg. 6.42% | Avg: $6.14B Low: $6.01B High: $6.28B avg. 7.96% | |
Net Income
% change YoY
| $779.43M N/A | $897.55M 15.15% | $1.02B 13.74% | Avg: $1.37B Low: $1.20B High: $1.49B avg. 34.94% | Avg: $1.50B Low: $1.46B High: $1.54B avg. 9.09% | Avg: $1.54B Low: $1.50B High: $1.59B avg. 3.00% | |
EBITDA
% change YoY
| $1.19B N/A | $1.35B 13.79% | $1.53B 12.86% | Avg: $1.77B Low: $1.73B High: $1.81B avg. 15.68% | Avg: $1.88B Low: $1.84B High: $1.92B avg. 6.42% | Avg: $2.03B Low: $1.99B High: $2.08B avg. 7.96% | |
EPS
% change YoY
| $5.34 N/A | $6.12 14.60% | $6.94 13.39% | Avg: $9.16 Low: $8.16 High: $10.14 avg. 32.03% | Avg: $10.19 Low: $9.91 High: $10.48 avg. 11.24% | Avg: $10.5 Low: $10.2 High: $10.8 avg. 3.00% | |
Operating Expenses
% change YoY
| $1.02B N/A | $1.20B 17.54% | $1.33B 10.94% | Avg: $1.17B Low: $1.15B High: $1.20B avg. -11.85% | Avg: $1.25B Low: $1.22B High: $1.28B avg. 6.42% | Avg: $1.35B Low: $1.32B High: $1.38B avg. 7.96% | |
FAQ
What is ResMed stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 15.68% in 2026-2028.
We have gathered data from 9 analysts. Their low estimate is 1.20B, average is 1.37B and high is 1.49B.
What is ResMed stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 9.54% in 2026-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $5.23B, average is $5.35B and high is $5.46B.
What is ResMed stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 15.42% in 2026-2028.
We have gathered data from 9 analysts. Their low earnings per share estimate is $8.16, average is $9.16 and high is $10.14.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering ResMed stock. The most successful analyst is Jonathan Block.